Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint Of Progression-Free Survival (Pfs) In Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 And In All Comers
May 15 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES PHASE 3 KEYNOTE-B96 TRIAL MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER WHOSE TUMORS EXPRESSED PD-L1 AND IN ALL COMERS
MERCK & CO INC - STUDY MEETS SECONDARY ENDPOINT OF OVERALL SURVIVAL
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.